Phase 3 data show consistent safety with repeat TrenibotE treatments, while survey findings highlight growing aesthetic demand among patients using GLP-1 weight loss drugs.
The expanded indication is based on clinical data showing high responder rates and results lasting up to 18 months, with no serious adverse events reported.
The company presented clinical data on its PCL-based collagen stimulator, positioning it within a shift toward treatments targeting skin laxity.
The device connects to standard operating room suction and is designed to support faster, more controlled explantation without requiring additional capital equipment or specialized training.
Plastic surgeons are calling for a ban on dermal fillers being injected into breasts, warning the procedure carries "unacceptable" risks.
